Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma

Leukemia

Volumn 24, Issue 5, 2010, Pages 1037-1042

  Palumbo, A ^a   Larocca, A ^a   Falco, P ^b   Sanpaolo, G ^c   Falcone, A P ^c   Federico, V ^d   Canepa, L ^e   Crugnola, M ^f   Genuardi, M ^a   Magarotto, V ^a   Petrucci, M T ^d   Boccadoro, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SC Medicina Trasfusionale Ed Ematologia ASL TO4   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF PARMA   (Italy)

Author keywords

Multiple myeloma; New drugs; Salvage therapy

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ADULT; AGED; ALLOTRANSPLANTATION; ANEMIA; ARTICLE; ATELECTASIS; BLOOD TOXICITY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; INFECTION; LUNG EDEMA; MALE; MENINGITIS; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPENIA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SEPTIC SHOCK; SIDE EFFECT; SUDDEN DEATH; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE;

EID: 77952429928     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.58     Document Type: Article

References (36)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488.
2. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1685.
3. Myeloma Trialist' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842.
4. Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high risk patients. J Clin Oncol 1991; 9: 444-448.
5. Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol 2004; 22: 3212-3214.
6. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
7. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
8. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
9. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
10. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
11. Cibeira MT, Rosiñol L, Ramiro L, Esteve J, Torrebadell M, Bladé J. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol 2006; 77: 486-492.
12. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8-11.
13. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
14. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M et al. A systematic review of phase II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Hematol 2006; 132: 584-593.
15. Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004; 73: 98-103.
16. Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5: 318-324.
17. Garća-Sanz R, González-Porras JR, Hernández JM, Polo-Zarzuela M, Sureda A, Barrenetxea C et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856-863.
18. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Eng J Med 2007; 357: 2123-2132.
19. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Eng J Med 2007; 357: 2133-2142.
20. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209-1218.
21. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825-831.
22. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27: 3664-3670.
23. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian multiple myeloma network. J Clin Oncol 2007; 25: 4459-4465.
24. Gandhi A, Zhang LH, Lu L, Bartlett B, Kang J, Schafer P et al. Effects and molecular mechanism of lenalidomide on FGFR signaling in endothelial cells and FGFR3 multiple myeloma cell lines. Haematologica 2006; 91 (Suppl 1): 274 (Abstract 745).
25. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT et al. Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
26. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380-386.
27. Zhang LH, Lu L, Wu L, Dredge K, Bartlett JK, Schafer P et al. Comparison of anti-angiogenic activities of thalidomide and lenalidomide in vitro. Proc Amer Assoc Cancer Res 2006; 47: 415 (Abstract 1761).
28. Palumbo A, Facon T, Sonneveld P, Bladè J, Offidani M, Gay F et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968-3977.
29. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354: 2079-2080.
30. Durie BG, Harousseau JL, Miguel JS, Bladè J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
31. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3. 0, DCTD, NCI, NIH, DHHS 31 March 2003. http://ctep.cancer.gov. Accessed 12 December 2003.
32. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
33. Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol 2006; 76: 273-277.
34. Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109: 2767-2772.
35. Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22: 2247-2256.
36. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al. Prevention of thalidomide and lenalidomide associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.